The NFL’s Bobby Wagner Negotiated His Own $54 Million Deal. Now The 30 Under 30 Linebacker Is Tackling Startups. [Forbes]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Forbes
S Considered That on-field success was just the beginning. This summer Wagner negotiated his own $54 million, three-year contract with the Seahawks, making him the highest-paid middle linebacker in the league. The deal not only upended the narrative that athletes can’t manage their own careers—or their finances—but also set him up with tens of millions of dollars in future cash flow earmarked for his own long-term wealth creation. “We get this money at such a young age,” says the All-Pro, recently selected to the 2020 Forbes For Wagner, who is also one of only four players to receive Madden NFL 20 “You've got to know what to look for,” Wagner says. “You have to have that type of focus and have that type of awareness.” Off the field it means knowing where to look, too—and which opportunities to tackle. Two years after turning pro, when he was earning half a million dollars per year, he met investor Robert Nelsen who at a financial seminar for athletes offered him an opportunity to plow
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- BioHive Announces BioHive Live [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at UBS Group AG from $70.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesPR Newswire
- Gain Therapeutics gets new chief medical officer [Seeking Alpha]Seeking Alpha
- Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- DNLI's page on the SEC website